Metabolomic Heterogeneity of Pulmonary Arterial Hypertension

Although multiple gene and protein expression have been extensively profiled in human pulmonary arterial hypertension (PAH), the mechanism for the development and progression of pulmonary hypertension remains elusive. Analysis of the global metabolomic heterogeneity within the pulmonary vascular system leads to a better understanding of disease progression. Using a combination of high-throughput liquid-and-gas-chromatography-based mass spectrometry, we showed unbiased metabolomic profiles of disrupted glycolysis, increased TCA cycle, and fatty acid metabolites with altered oxidation pathways in the human PAH lung. The results suggest that PAH has specific metabolic pathways contributing to increased ATP synthesis for the vascular remodeling process in severe pulmonary hypertension. These identified metabolites may serve as potential biomarkers for the diagnosis of PAH. By profiling metabolomic alterations of the PAH lung, we reveal new pathogenic mechanisms of PAH, opening an avenue of exploration for therapeutics that target metabolic pathway alterations in the progression of PAH.

[1]  福田 恵一 5th World Symposium on Pulmonary Hypertension , 2013 .

[2]  M. Humbert,et al.  Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.

[3]  Liang Huang,et al.  Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis , 2012, Leukemia & lymphoma.

[4]  R. Hamid,et al.  Pulmonary Circulation | April-june 2012 | Vol 2 | No 2 Research Ar Ticle Metabolomic Analysis of Bone Morphogenetic Protein Receptor Type 2 Mutations in Human Pulmonary Endothelium Reveals Widespread Metabolic Reprogramming Several Animal Models of Pah , 2022 .

[5]  R. Tuder,et al.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. , 2012, American journal of respiratory and critical care medicine.

[6]  T. Rice,et al.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  J. Foster,et al.  A retrospective review of the roles of multifunctional glucose-6-phosphatase in blood glucose homeostasis: Genesis of the tuning/retuning hypothesis. , 2010, Life sciences.

[8]  G. Lopaschuk,et al.  Fatty Acid Oxidation and Malonyl-CoA Decarboxylase in the Vascular Remodeling of Pulmonary Hypertension , 2010, Science Translational Medicine.

[9]  E. K. Weir,et al.  Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.

[10]  M. Humbert,et al.  Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. , 2009, The Journal of clinical investigation.

[11]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[12]  I. Haber,et al.  The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle , 2009, Journal of Molecular Medicine.

[13]  Peng Huang,et al.  Redox regulation of cell survival. , 2008, Antioxidants & redox signaling.

[14]  S. Rich,et al.  A USA-based registry for pulmonary arterial hypertension: 1982–2006 , 2007, European Respiratory Journal.

[15]  Peng Huang,et al.  The Warburg effect and its cancer therapeutic implications , 2007, Journal of bioenergetics and biomembranes.

[16]  Ahmad Y. Sheikh,et al.  Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-&ggr; Activation , 2007 .

[17]  Ahmad Y. Sheikh,et al.  Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. , 2007, Circulation.

[18]  D. Stewart,et al.  Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease , 2005, Circulation research.

[19]  Peng Huang,et al.  Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.

[20]  J. Dyck,et al.  Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.

[21]  J. Dyck,et al.  Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels , 2002, Circulation.

[22]  G. Semenza,et al.  Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[23]  M. Rabinovitch The committed vascular smooth muscle cell: a question of "timing" or "response to pressure" or both. , 1997, American journal of respiratory cell and molecular biology.

[24]  R. Wagner,et al.  Comparative analysis of glucose and glutamine metabolism in transformed mammalian cell lines, insect and primary liver cells , 1996, Journal of cellular physiology.

[25]  H. Schulz,et al.  beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. , 1995, Progress in lipid research.

[26]  P. Lazarow Rat liver peroxisomes catalyze the beta oxidation of fatty acids. , 1978, The Journal of biological chemistry.

[27]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.